Recent Company News

• 03:58 AM ET Dec 12, 2025
  

  NMPA approves Sino Biopharma's culmerciclib to market for combination therapy of breast cancer (HK$6.80, 0.00)

• 08:33 PM ET Dec 07, 2025
  

  StreetAccount China Healthcare Sector Update: China reveals 2025 National Reimbursement Drug List, 114 newly added, 19 made commercial insurance list

• 07:24 AM ET Dec 07, 2025
  

  Akeso's five drugs included in 2025 NRDL in China (HK$124.10, 0.00)

• 04:28 AM ET Dec 04, 2025
  

  Sino Biopharmaceutical obtains NMPA and FDA approvals for clinical trial of TQF3250 for weight loss (HK$6.88, 0.00)

• 03:44 AM ET Dec 03, 2025
  

  NMPA approves Rotigotine Patch for marketing (HK$6.75, 0.00)

• 03:54 AM ET Dec 02, 2025
  

  StreetAccount Sector Summary - China Healthcare November Recap

• 05:24 AM ET Dec 01, 2025
  

  Sino Biopharmaceutical enrolls first patient in phase I clinical trial of TRD208 in China (HK$6.92, 0.00)

• 04:44 AM ET Nov 18, 2025
  

  Sino Biopharmaceutical receives NMPA clinical trial approval for LM-350 in China (HK$6.98, 0.00)

• 10:51 PM ET Nov 12, 2025
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 10:36 PM ET Nov 12, 2025
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning